At Capellon Pharmaceuticals, our branded products improve the lives of people everyday. We market pharmaceutical products in several important therapeutic areas such as: allergy, respiratory, and gastroenterology.

Capellon Pharmaceuticals, Ltd., was founded in January 1999 by executives with over 65 years in the pharmaceutical business. Capellon Pharmaceuticals, Ltd., is an exciting, growth-orientated prescription pharmaceutical company headquartered in Fort Worth, Texas. We market pharmaceutical products in several important therapeutic areas such as: allergy, respiratory, and gastroenterology. At Capellon Pharmaceuticals, our branded products improve the lives of people everyday.

The company's strategy is twofold: first implement significant marketing and promotional efforts on targeted populations for our existing brands; and secondly acquire and license additional products that can be effectively marketed within these customer populations. We intend to sustain profitable growth through our acquisition and licensing activities and by forming partnerships with existing pharmaceutical companies. Capellon focuses significant product marketing and promotional efforts on target customer populations while working within all healthcare, distribution and provider channels to achieve medical management to the patient.

Capellon Pharmaceuticals is a recognized leader in specialty markets and provides value to its customers, healthcare providers and healthcare consumers.

The Star in Capellon represents the fact that we are a Texas based company. More importantly, the five pointed star represents Capellon's "Five Points of Excellence" as follows:

Provide safe, effective, quality products at an affordable price to the healthcare consumer.

Focus on the healthcare provider and provide only the highest level of support and service.

Conduct all business dealings with honesty, professionalism and integrity.

Maximize human capital by hiring, training and retaining only the best employees.

Seek new marketing opportunities and maximize potential of current product portfolio.